AG2R LA Mondiale Gestion D Actifs Takes Position in Insulet Corporation $PODD

AG2R LA Mondiale Gestion D Actifs bought a new stake in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 4,293 shares of the medical instruments supplier’s stock, valued at approximately $1,349,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in Insulet by 4.3% in the 1st quarter. GAMMA Investing LLC now owns 2,529 shares of the medical instruments supplier’s stock valued at $664,000 after acquiring an additional 105 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Insulet by 13.9% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,028 shares of the medical instruments supplier’s stock valued at $795,000 after purchasing an additional 370 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Insulet by 2.9% in the first quarter. Janney Montgomery Scott LLC now owns 5,405 shares of the medical instruments supplier’s stock worth $1,419,000 after purchasing an additional 154 shares during the period. Asset Management One Co. Ltd. lifted its position in Insulet by 4.0% in the first quarter. Asset Management One Co. Ltd. now owns 27,824 shares of the medical instruments supplier’s stock worth $7,307,000 after purchasing an additional 1,058 shares during the period. Finally, Golden State Wealth Management LLC boosted its stake in Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 177 shares in the last quarter.

Insiders Place Their Bets

In other Insulet news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Wall Street Analyst Weigh In

PODD has been the subject of a number of analyst reports. Oppenheimer raised their price objective on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. JPMorgan Chase & Co. raised their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Stifel Nicolaus assumed coverage on Insulet in a report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective on the stock. Piper Sandler increased their target price on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $352.11.

Insulet Trading Down 0.8%

Shares of NASDAQ PODD opened at $320.91 on Friday. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50. The company has a 50-day moving average of $327.60 and a two-hundred day moving average of $304.83. The company has a market cap of $22.59 billion, a PE ratio of 97.54, a P/E/G ratio of 2.68 and a beta of 1.40. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter last year, the business posted $0.55 earnings per share. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.